Cystadenocarcinoma, Serous clinical trials
The registry lists 15 studies for Cystadenocarcinoma, Serous across more than 10 countries. 1 are recruiting or about to start. 4 of them are mainly about Cystadenocarcinoma, Serous (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-02.
Get an email when these change. Save the Cystadenocarcinoma, Serous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (3) · Hospices Civils de Lyon (1) · Blokhin's Russian Cancer Research Center (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Incyte Corporation (1) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (1) · University Health Network, Toronto (1) · Gynecologic Oncology Group (1)
What is being tested here
Drugs under test in Cystadenocarcinoma, Serous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Niraparib | 1 | 1 | 3 |
| Pembrolizumab | 0 | 0 | 1 |
| Ipilimumab | 0 | 0 | 1 |
| Nivolumab | 0 | 0 | 1 |
| Ribociclib | 0 | 0 | 1 |
| Letrozole | 0 | 0 | 1 |
| Trametinib dimethyl sulfoxide | 0 | 1 | 1 |
| Trametinib | 0 | 1 | 1 |
| Azenosertib | 0 | 0 | 1 |
| AZD 6244 | 0 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 3
Who these studies take
Of the 1 Cystadenocarcinoma, Serous studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 1 (100%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 0 (0%) |
| 30 | 1 (100%) | 0 (0%) |
| 40 | 1 (100%) | 0 (0%) |
| 50 | 1 (100%) | 0 (0%) |
| 65 | 1 (100%) | 0 (0%) |
| 75 | 1 (100%) | 0 (0%) |
| 85 | 1 (100%) | 0 (0%) |
Across all 15 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 13% take children; 87% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 15 of 15. search them.
- Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingNCT04716686Phase 21 country
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 21 country
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedNCT02101788Phase 2/32 countries
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/21 country
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedNCT04814108Phase 24 countries
- Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 21 country
- A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerTerminatedNCT04159155Phase 2/31 country
- Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable1 country
- Niraparib in High-grade Endometrial Cancer TrialWithdrawnNCT05289648Early Phase 1
- Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum CancerCompletedNCT00551070Phase 21 country
- Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageStatus unknownNCT03150121Not applicable1 country
- Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)Status unknownNCT04055038Phase 2/31 country
- French National Registry of Rare Peritoneal Surface MalignanciesStatus unknownNCT028341691 country
- Papillary Serous Carcinoma of the EndometriumCompletedNCT00515073Phase 21 country